Fundraising Fox

TORL BioTherapeutics

Culver City, US · Delaware LLC · 5 known investors

Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.

Biotech

Founders & leadership

MA
Mark AllesNamed on SEC filing
MA
Mark AttanasioNamed on SEC filing
DL
David LicataNamed on SEC filing
NO
Neil O'BrienNamed on SEC filing
AS
Amit SinhaNamed on SEC filing
LS
Lynn SeelyNamed on SEC filing
DS
Dennis SlamonNamed on SEC filing

Investors · 5

OCV PartnersLos Angelesvia Chris Bostick · led
Cowen Healthcare InvestmentsreportedNew York
Goldman SachsreportedNew York
Perceptive Xontogeny VenturereportedNew York
Vertex Ventures HCreportedSingapore · $500K – $10M

Funding

SEC filings, press & company announcements

$254.3M disclosed across 2 of 3 rounds · 2023–2025

▶$158.3MraisedApr 2024 · 52 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark AllesExecutive Officer, Director
  • Mark AttanasioDirector
  • David LicataExecutive Officer, Director
  • Neil O'BrienDirector
  • Amit SinhaDirector
  • Lynn SeelyDirector
  • Dennis SlamonDirector
Offering amount
$158.3M
Amount sold
$158.3M
First sale
Apr 2024
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

TORL BioTherapeutics Raises $96M Series C to Advance Claudin 6-Targeted ADC for Platinum-Resistant Ovarian Cancertrial.medpath.com · Oct 2025TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congressprnewswire.com · Oct 2025Mark Alles’ biotech gets $96M for ADCs from UCLA labendpoints.news · Oct 2025TORL BioTherapeutics Raises $158M in Series B Financingfinsmes.com · Apr 2023TORL BioTherapeutics Launches with $158M to Develop Novel Oncology Biologicsbiopharmaboardroom.com

Frequently asked questions

What does TORL BioTherapeutics do?
Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.
Who are TORL BioTherapeutics's investors?
TORL BioTherapeutics's investors include OCV Partners, Cowen Healthcare Investments, Goldman Sachs, Perceptive Xontogeny Venture, Vertex Ventures HC.
How much funding has TORL BioTherapeutics raised?
TORL BioTherapeutics has disclosed $254.3M raised across 2 of its 3 known rounds.
Where is TORL BioTherapeutics headquartered?
TORL BioTherapeutics is headquartered in Culver City, US.